Table 1 Description of the sample.
Variable | Frequency (%) |
|---|---|
Sex | |
Men | 76 (21.3) |
Women | 280 (78.7) |
Age at diagnosis (mean; median (P25–P75)) | |
Overall | 68; 70 (60–78) |
Men | 67.4; 67.5 (59.8–79.3) |
Women | 68.2; 71 (60–78) |
Residential radon concentration (mean; median (P25–P75)) | 256.5; 178 (109–330.5) |
Histologic type | |
Adenocarcinoma | 295 (82.9) |
Squamous | 34 (9.6) |
Large cell | 8 (2.2) |
Other | 19 (5.3) |
Diagnostic stage | |
I | 42 (12.1) |
II | 23 (6.6) |
III | 58 (16.7) |
IV | 225 (64.6) |
Environmental tobacco smoke exposure | 153 (43.3) |
Mutation data | |
EGFR | 130 (35.2) |
ALK | 21 (5.7) |
ROS1 | 1 (0.3) |
Treatments | |
Chemotherapy | 85 (24.7) |
Radiotherapy | 37 (10.8) |
Chemo-radiotherapy | 94 (27.3) |
Others | 128 (37.2) |
GSTM1 | |
Salvage gene/heterozygous | 86 (48.3) |
Homozygous | 92 (51.7) |
GSTT1 | |
Salvage gene/heterozygous | 128 (74.4) |
Homozygous | 44 (25.6) |
XRCC1 rs25487 | |
GG | 155 (47) |
AG | 132 (40) |
AA | 43 (13) |
ERCC1 rs11615 | |
CC | 55 (16.7) |
CT | 163 (49.4) |
TT | 112 (33.9) |
ERCC1 rs3212986 | |
GG | 177 (53.6) |
GT | 131 (39.7) |
TT | 22 (6.7) |
ERCC2 rs13181 | |
TT | 140 (42.4) |
GT | 154 (46.7) |
GG | 36 (10.9) |
XRCC3 rs861539 | |
CC | 120 (36.4) |
TC | 168 (50.9) |
TT | 42 (12.7) |
OGG1 rs1052133 | |
CC | 204 (61.8) |
CG | 109 (33) |
GG | 17 (5.2) |
Alpha-1-antytripsin | |
MM | 235 (71.6) |
MS | 72 (22) |
MZ | 11 (3.4) |
SZ | 3 (0.9) |
SS | 7 (2.1) |
Type of toxicitya | |
Anti-EGFR toxicoderma | 48 (13) |
Neutropenia | 19 (5.1) |
Hepatotoxicity | 3 (0.8) |
Diarrhea | 9 (2.4) |
Nausea/vomiting | 20 (5.4) |
